Pharmaceutical Companies

Pomerantz Law Firm Investigates Claims on Behalf of Investors of Pharmasset, Inc.

Published in Pharma Law Weekly, December 6th, 2011

2011 DEC 6 -- Pomerantz Haudek Grossman & Gross LLP is investigating claims on behalf of investors of Pharmasset, Inc. ("Pharmasset" or the "Company") (NASDAQ: VRUS) concerning the proposed acquisition of Pharmasset by Gilead Sciences, Inc. in a cash transaction valued at $11 billion.

The investigation concerns whether the board of directors are breaching their fiduciary duties by failing to adequately shop the Company and maximize shareholder value. Under the terms of the agreement, Pharmasset shareholders would receive $137 per share in a cash tender offer. However, the Company has three clinical-stage product candidates for the treatment of chronic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly

Source: Pharma Law Weekly (2011-12-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry